Literature DB >> 17034569

Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity.

R Kim1, M Emi, K Tanabe.   

Abstract

Dendritic cells play a crucial role in initiating tumour immunity as well as in the immune response for invading foreign pathogens such as bacteria and viruses. For bacterial and viral infections, the immature dendritic cells (iDCs) residing in peripheral tissues are efficiently activated and matured by pathogen signals for performing the immune response. In contrast, for self-antigens, the naive T cells are not activated by iDCs but proceed to anergy/deletion, and the generation of regulatory T cells for immune tolerance. The induction of immune response and tolerance is regulated strictly by iDCs as the sensor for homeostasis of immune response in the host. Despite the identification of some tumour antigens, tumour immunity is not provoked successfully. Even though there are some critical obstacles to inhibit effective tumour immunity, tumour cells are able to exploit the functional roles of iDCs for tumour progression, which are induced by tumour-derived soluble factors such as vascular endothelial growth factor (VEGF) and functionally modulated in the microenvironment. The iDCs still remain as the critical target for provoking tumour immunity. In this review, the functional roles of tumour-associated iDCs and the strategy for targeting iDCs in effective tumour immunity for the cancer patient are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17034569      PMCID: PMC1942049          DOI: 10.1111/j.1365-2249.2006.03215.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  77 in total

Review 1.  Antigen presentation to naive CD4 T cells in the lymph node.

Authors:  Andrea A Itano; Marc K Jenkins
Journal:  Nat Immunol       Date:  2003-08       Impact factor: 25.606

2.  Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon.

Authors:  Agnes Le Bon; Nathalie Etchart; Cornelia Rossmann; Miranda Ashton; Sam Hou; Dirk Gewert; Persephone Borrow; David F Tough
Journal:  Nat Immunol       Date:  2003-09-21       Impact factor: 25.606

3.  VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.

Authors:  Joyce E Ohm; Dmitry I Gabrilovich; Gregory D Sempowski; Ekaterina Kisseleva; Kelly S Parman; Sorena Nadaf; David P Carbone
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

4.  Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA.

Authors:  Sandra S Diebold; Tsuneyasu Kaisho; Hiroaki Hemmi; Shizuo Akira; Caetano Reis e Sousa
Journal:  Science       Date:  2004-02-19       Impact factor: 47.728

Review 5.  Dendritic cells as vectors for immunotherapy of cancer.

Authors:  Sophie Paczesny; Hideki Ueno; Joseph Fay; Jacques Banchereau; A Karolina Palucka
Journal:  Semin Cancer Biol       Date:  2003-12       Impact factor: 15.707

6.  The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily.

Authors:  Florian Heil; Parviz Ahmad-Nejad; Hiroaki Hemmi; Hubertus Hochrein; Franziska Ampenberger; Tanja Gellert; Harald Dietrich; Grayson Lipford; Kiyoshi Takeda; Shizuo Akira; Hermann Wagner; Stefan Bauer
Journal:  Eur J Immunol       Date:  2003-11       Impact factor: 5.532

Review 7.  Central memory and effector memory T cell subsets: function, generation, and maintenance.

Authors:  Federica Sallusto; Jens Geginat; Antonio Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

8.  Molecular identification of a danger signal that alerts the immune system to dying cells.

Authors:  Yan Shi; James E Evans; Kenneth L Rock
Journal:  Nature       Date:  2003-09-07       Impact factor: 49.962

9.  The induction of tolerance by dendritic cells that have captured apoptotic cells.

Authors:  R M Steinman; S Turley; I Mellman; K Inaba
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

10.  Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells.

Authors:  Sayuri Yamazaki; Tomonori Iyoda; Kristin Tarbell; Kara Olson; Klara Velinzon; Kayo Inaba; Ralph M Steinman
Journal:  J Exp Med       Date:  2003-07-21       Impact factor: 14.307

View more
  23 in total

1.  Studies of amplification, identification and resistant to maturation characteristics on immature dendritic cells derived from human peripheral blood in vitro.

Authors:  Haiming Xin; Wenxian Yang; Yan Jiang; Yitao Wang; Yalin Tong; Yizhi Peng
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-08-15       Impact factor: 2.416

2.  Adenovirus co-expressing CD40 ligand and interleukin (IL)-2 contributes to maturation of dendritic cells and production of IL-12.

Authors:  Zhi Guo; Hong-Yan Gao; Tian-Yang Zhang; Jin-Xing Lou; Kai Yang; Xiao-Dong Liu; Xue-Peng He; Hui-Ren Chen
Journal:  Biomed Rep       Date:  2016-10-06

3.  High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.

Authors:  Chuan-Yong Mu; Jian-An Huang; Ying Chen; Cheng Chen; Xue-Guang Zhang
Journal:  Med Oncol       Date:  2010-04-06       Impact factor: 3.064

4.  Immunosuppressive mechanisms of regulatory dendritic cells in cancer.

Authors:  Galina V Shurin; Yang Ma; Michael R Shurin
Journal:  Cancer Microenviron       Date:  2013-06-09

Review 5.  Tumor associated regulatory dendritic cells.

Authors:  Yang Ma; Galina V Shurin; Dmitriy W Gutkin; Michael R Shurin
Journal:  Semin Cancer Biol       Date:  2012-03-06       Impact factor: 15.707

Review 6.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

Review 7.  Immunotherapy for melanoma: current status and perspectives.

Authors:  Doru T Alexandrescu; Thomas E Ichim; Neil H Riordan; Francesco M Marincola; Anna Di Nardo; Filamer D Kabigting; Constantin A Dasanu
Journal:  J Immunother       Date:  2010 Jul-Aug       Impact factor: 4.456

Review 8.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

9.  Salmonella typhimurium stimulation combined with tumour-derived heat shock proteins induces potent dendritic cell anti-tumour responses in a murine model.

Authors:  D A Shilling; M J Smith; R Tyther; D Sheehan; K England; E G Kavanagh; H P Redmond; F Shanahan; L O'Mahony
Journal:  Clin Exp Immunol       Date:  2007-04-25       Impact factor: 4.330

10.  A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.

Authors:  Sachin Gupta; James M Termini; Yaelis Rivas; Miguel Otero; Francesca N Raffa; Vikas Bhat; Amjad Farooq; Geoffrey W Stone
Journal:  Vaccine       Date:  2015-08-01       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.